The Claim
In adults with obesity prescribed semaglutide for 12 months, those without type 2 diabetes experience a mean weight loss of 16.9%, while those with type 2 diabetes experience a mean weight loss of 9.9%, demonstrating a differential response to semaglutide based on metabolic status.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Among adults with obesity taking semaglutide for a year, those without type 2 diabetes lost an average of 16.9% of their body weight, while those with type 2 diabetes lost an average of 9.9%.
See the scientific wording
In adults with obesity prescribed semaglutide for 12 months, those without type 2 diabetes achieved a mean weight loss of 16.9% compared to 9.9% in those with type 2 diabetes, indicating a differential response based on metabolic status.
In people with type 2 diabetes, the body’s response to the weight-loss hormone semaglutide is weaker because their cells have become less sensitive to it over time due to long-term high blood sugar and insulin resistance. This means the drug doesn’t reduce hunger or boost calorie burning as much as it does in people without diabetes.
What the research says
1 studyStudy: Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study
People without diabetes who took semaglutide for a year lost almost 17% of their body weight, while those with diabetes lost about 10%. The study shows that having diabetes makes the weight loss drug less effective.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.